All Title Author
Keywords Abstract

PLOS ONE  2014 

PROgnosticating COeliac patieNts SUrvivaL: The PROCONSUL Score

DOI: 10.1371/journal.pone.0084163

Full-Text   Cite this paper   Add to My Lib


Introduction It has been shown that mortality rates of coeliac patients correlate with age at diagnosis of coeliac disease, diagnostic delay for coeliac disease, pattern of clinical presentation and HLA typing. Our aim was to create a tool that identifies coeliac patients at higher risk of developing complications. Methods To identify predictors of complications in patients with coeliac disease, we organised an observational multicenter case-control study based on a retrospective collection of clinical data. Clinical data from 116 cases (patients with complicated coeliac disease) and 181 controls (coeliac patients without any complications) were collected from seven European centres. For each case, one or two controls, matched to cases according to the year of assessment, gender and age, were selected. Diagnostic delay, pattern of clinical presentation, HLA typing and age at diagnosis were used as predictors. Results Differences between cases and controls were detected for diagnostic delay and classical presentation. Conditional logistic models based on these statistically different predictors allowed the development of a score system. Tertiles analysis showed a relationship between score and risk of developing complications. Discussion A score that shows the risk of a newly diagnosed coeliac patient developing complications was devised for the first time. This will make it possible to set up the follow-up of coeliac patients with great benefits not only for their health but also for management of economic resources. Conclusions We think that our results are very encouraging and represent the first attempt to build a prognostic score for coeliac patients.


[1]  Dubé C, Rostom A, Sy R, Cranney A, Saloojee N, et al. (2005) The prevalence of celiac disease in average-risk and at-risk Western European populations: a systematic review. Gastroenterology 128 (4 Suppl 1)S57–67.
[2]  Biagi F, Gobbi P, Marchese A, Borsotti E, Zingone F, et al.. (2013) Low incidence but poor prognosis of complicated coeliac disease: a retrospective multicentre study. Dig Liver Dis
[3]  Biagi F, Corazza GR (2010) Mortality in celiac disease. Nat Rev Gastroenterol Hepatol 7: 158–162.
[4]  Biagi F, Lorenzini P, Corazza GR. (2000) Literature review on the clinical relationship between ulcerative jejunoileitis, coeliac disease, and enteropathy-associated T-cell. Scand J Gastroenterol 35: 785–790.
[5]  Mearin ML, Catassi C, Brousse N, Brand R, Collin P, et al. (2006) European multi-centre study on coeliac disease and non-Hodgkin lymphoma. Eur J Gastroenterol Hepatol 18: 187–194.
[6]  Malamut G, Cellier C (2011) Is refractory celiac disease more severe in old Europe? Am J Gastroenterol 106: 929–932.
[7]  West J (2009) Celiac disease and its complications: a time traveller’s perspective. Gastroenterology 136: 32–34.
[8]  Roshan B, Leffler DA, Jamma S, Dennis M, Shets S, et al. (2011) The incidence and clinical spectrum of refractory celiac disease in a north american referral center. Am J Gastroenterol 106: 923–928.
[9]  Di Sabatino A, Biagi F, Gobbi PG, Corazza GR (2012) How I treat enteropathy-associated T-cell lymphoma. Blood 119: 2458–2468.
[10]  Malamut G, Afchain P, Verkarre V, Lecomte T, Amiot A, et al. (2009) Presentation and long-term follow-up of refractory celiac disease: comparison of type I with type II. Gastroenterology 136: 81–90.
[11]  Al-Toma A, Verbeek WH, Hadithi M, von Blomberg BM, Mulder CJ (2007) Survival in refractory coeliac disease and enteropathy-associated T-cell lymphoma: retrospective evaluation of single-centre experience. Gut 56: 1373–1378.
[12]  Daum S, Ipczynski R, Schumann M, Wahnschaffe U, Zeitz M (2009) High rates of complications and substantial mortality in both types of refractory sprue. Eur J Gastroenterol Hepatol 21: 66–70.
[13]  Rubio-Tapia A, Kelly DG, Lahr BD, Dogan A, Wu TT, et al. (2009) Clinical staging and survival in refractory celiac disease: a single center experience. Gastroenterology 136: 99–107.
[14]  Gale J, Simmonds PD, Mead GM, Sweetenham JW, Wright DH (2000) Enteropathy-type intestinal T-cell lymphoma: clinical features and treatment of 31 patients in a single center. J Clin Oncol 18: 795–803.
[15]  Corrao G, Corazza GR, Bagnardi V, Brusco G, Ciacci C, et al. (2001) Mortality in patients with coeliac disease and their relatives: a cohort study. Lancet 358: 356–361.
[16]  Murray JA, Moore SB, Van Dyke CT, Lahr BD, Dierkhising RA, et al. (2007) HLA DQ gene dosage and risk and severity of celiac disease. Clin Gastroenterol Hepatol 5: 1406–1412.
[17]  Al-Toma A, Goerres MS, Meijer JWR, Pe?a AS, Crusius JB, et al. (2006) Human leukocyte antigen-DQ2 homozygosity and the development of refractory celiac disease and enteropathy associated T-cell lymphoma. Clin Gastroenterol Hepatol 4: 315–319.
[18]  Biagi F, Bianchi PI, Vattiato C, Marchese A, Trotta L, et al. (2012) The influence of HLA-DQ2 and DQ8 on severity in celiac disease. J Clin Gastroenterol 46: 46–50.
[19]  Ludvigsson JF, Leffler DA, Bai J, Biagi F, Fasano A, et al. (2013) The Oslo definitions for coeliac disease and related terms. Gut 62: 43–52.
[20]  Peduzzi P, Concato J, Kemper E, Holford TR, Feinstein AR (1996) A simulation study of the number of events per variable in logistic regression analysis. J Clin Epidemiol 49: 1373–1379.
[21]  Rubio-Tapia A, Hill ID, Kelly CP, Calderwood AH, Murray JA (2013) ACG clinical guidelines: diagnosis and management of celiac disease. Am J Gastroenterol 108: 656–676.
[22]  Peters U, Askling J, Gridley G, Ekbom A, Linet M (2003) Causes of death in patients with celiac disease in a population-based Swedish cohort. Arch Intern Med 163: 1566–1572.


comments powered by Disqus